(Q35020524)

5 August 2017

1 reference

title

Taxanes for advanced non-small cell lung cancer (English)

1 reference

5 August 2017

1 reference

Sakkaraiappan Ramalingam

series ordinal

1

1 reference

5 August 2017

Chandra P Belani

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1693-1709

1 reference

Regional lymph node classification for lung cancer staging

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Docetaxel versus paclitaxel for antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Cell surface receptors that serve to transport ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1693

10.1517/14656566.3.12.1693

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference